EBS Q3 2020 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

Q3 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$385M+23.5% YoY

Gross Profit

$181M46.9% margin

Operating Income

$61M15.9% margin

Net Income

$40M10.3% margin

EPS (Diluted)

$0.73

QoQ Revenue Growth

-2.4%

Cash Flow

Operating Cash Flow

$105M

Free Cash Flow

$60M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$2.6B

Total Liabilities

$1.4B

Stockholders' Equity

$1.3B

Cash & Equivalents

$415M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$385M	$312M	+23.5%
Gross Profit	$181M	$150M	+20.2%
Operating Income	$61M	$71M	-13.3%
Net Income	$40M	$43M	-8.6%

Revenue Segments

Product

$202M52%

Contract Development And Manufacturing

$157M41%

Contracts and Grants

$26M7%

Geographic Segments

UNITED STATES

$213M55%

Non-US

$172M45%